Arcadia Biosciences stock faces a Nasdaq compliance deadline

Published on 09/30/2026 at 08:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Arcadia Biosciences stock has a USD 0.4 million market value as of September 29, 2026. Q2 revenue reached USD 1.4 million, while cash stood at USD 4.2 million.

RKDA, US03020Q1058, Illustration mit AI erstellt.

Arcadia Biosciences (ISIN US03020Q1058) faces a Nasdaq compliance deadline after reporting stockholders' equity of USD 633,000 as of June 30, 2026. StockTitan reports that the company has until October 15, 2026, to submit a plan addressing the Nasdaq Capital Market requirement.

Equity gap sets October deadline

The Nasdaq standard requires at least USD 2.5 million in stockholders' equity, leaving Arcadia USD 1.9 million below that threshold based on the June 30 figure. The common stock continues trading on the Nasdaq Capital Market under RKDA while the compliance process runs.

The notice dated August 31, 2026 gives Arcadia 45 days to present its plan, according to StockTitan. The company may receive an initial 180-day period if Nasdaq accepts the plan, making the October filing a key near-term corporate event.

Q2 loss reaches USD 6.3 million

Arcadia reported Q2 2026 revenue of USD 1.4 million and first-half revenue of USD 2.5 million, according to StockTitan. Net loss attributable to common stockholders reached USD 6.3 million for the quarter and USD 10.7 million for the first half.

Cash and cash equivalents stood at USD 4.2 million on June 30, 2026, while cash used in operating activities was USD 319,000 in Q2. The company describes its business as agricultural innovation focused on crops and plant-based wellness products in its investor materials.

Market value remains highly volatile

Arcadia's market capitalization stood at USD 0.4 million on September 29, 2026. Its 52-week range was USD 0.25 to USD 6.71, putting the latest market value close to the bottom of that interval and underscoring the importance of the listing process.

Shareholders also approved a reverse stock split authorization ranging from 1-for-2 to 1-for-10 at the September 10, 2026 annual meeting, according to Quartr. That authorization gives the board another capital-markets tool before June 30, 2027.

Market value and listing

Arcadia Biosciences had a market capitalization of USD 0.4 million on September 29, 2026. The shares are listed on the Nasdaq Capital Market under RKDA, and the company operates in agricultural inputs.